Page 123 - Libro Memoria Cien Inglés
P. 123
researchers, government agencies and EUROPEAN UNION JOINT PRO-
pharmaceutical and biotechnology GRAMMING ON NEURODEGE-
companies is an essential ingredient NERATIVE DISEASE RESEARCH
in promoting this type of ambitious (JPND)
initiatives, especially when resources The EU Joint Programming for Re-
are limited. search in Neurodegenerative Diseases
In this context, in recent years CIEN (JPND) is an innovative collaborative
Foundation together with the Network research initiative created to address
Center for Biomedical Research in the growing challenges posed by the-
Neurodegenerative Diseases (CIBER- se disorders. The JPND is a pioneering
NED, for its acronym in Spanish) has example of joint programming for the
given a boost to its relations with inter- promotion of research within the Euro-
national organizations in the area of re- pean Union aimed at scientific challen-
search in neurodegenerative diseases ges requiring a response that exceeds
such as the EU Joint Programme for the capacity of a single country, based
Research in Neurodegenerative Disea- on the alignment of national research
ses (JPND) and the Network of Centers programs devoted to these challen-
of Excellence in Neurodegeneration ges. Its objective is to enhance the
(COEN), among other initiatives. impact of research by aligning existing
national research programs and the
Although 2020 has not been very identification of common objectives
productive in terms of international whose scope would benefit from joint
collaborations, these and other inter- action. The JPND Scientific Advisory
nationalization activities carried out Committee has significant participa-
during 2020 by the CIEN Foundation tion of two CIBERNED researchers, Drs.
are detailed below. Jesús Avila and Jesús de Pedro, as well
as Dr. Angel Cedazo-Mínguez, from the
Karolinska Institute in Stockholm and
member of the CIBERNED Scientific
External Advisory Committee.
The Research Strategy designed by
JPND provides a framework for futu-
re investments and shows that the
research effort within the European
Union can be leveraged to improve
care on prevention, diagnosis and
treatment of patients suffering from
these diseases.
